<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Randomized trials of axillary lymph node management in early breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Randomized trials of axillary lymph node management in early breast cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Randomized trials of axillary lymph node management in early breast cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="10%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Study name</td> <td class="subtitle1">Study population</td> <td class="subtitle1">Mean follow-up</td> <td class="subtitle1" colspan="2">Comparison</td> <td class="subtitle1">Primary outcome</td> <td class="subtitle1">Additional outcomes</td> <td class="subtitle1">Morbidity</td> </tr> <tr> <td class="subtitle2_left" colspan="8">RCTs comparing SLNB with ALND</td> </tr> <tr class="divider_bottom"> <td class="indent1">NSABP B32 (2010)<sup>[1,2]</sup></td> <td>5611 women with mostly &lt;4 cm invasive breast cancer</td> <td>96 months</td> <td>SLNB + ALND</td> <td>SLNB alone (if negative)</td> <td>OS: no difference</td> <td> <p>DFS: no difference</p> Axillary recurrence: no difference</td> <td>ALND caused fewer shoulder abduction deficits, less arm volume difference (lymphedema), and less patient-reported arm numbness or tingling throughout a three-year follow-up period.</td> </tr> <tr class="divider_bottom"> <td class="indent1">ALMANAC (2006)<sup>[3]</sup></td> <td>1031 women with clinically node-negative breast cancer</td> <td>12 months</td> <td>ALND</td> <td> <p>SLNB alone (if negative)</p> SLNB + ALND or axillary RT (if positive)</td> <td>Arm/shoulder morbidity and Quality of Life (QOL)</td> <td> </td> <td> <p>SLNB causes less lymphedema and sensory loss than ALND (relative risk 0.37 and 0.37).</p> <p>Drain use, length of hospital stay, and time to normal activity were all lower in SLNB group.</p> Patient-recorded QOL and arm functioning scores were better in SLNB group.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Veronesi (2010)<sup>[4,5]</sup></td> <td>516 women with &lt;2 cm breast cancer</td> <td>102 months</td> <td>SLNB + ALND</td> <td>SLNB alone (if negative)</td> <td>DFS: no difference</td> <td> <p>OS: no difference</p> Breast cancer related events or death: no difference</td> <td>NR</td> </tr> <tr class="divider_bottom"> <td class="indent1">Cambridge/East Anglia study group (2005)<sup>[6]</sup></td> <td>298 patients with &lt;3 cm breast cancer</td> <td>12 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td>Postoperative morbidity</td> <td> </td> <td> <p>SLNB caused a reduction in postoperative arm swelling, subjective lymphedema, seroma formation, numbness, loss of sensitivity to light touch and pinprick, and paresthesia.</p> <p>SLNB was associated with less impairment in shoulder mobility.</p> Scores reflecting QOL and psychological morbidity were better in SLNB group.</td> </tr> <tr class="divider_bottom"> <td class="indent1">RACS/SNAC (2004)<sup>[7]</sup></td> <td>1088 women with clinically node-negative breast cancer</td> <td>36 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td>Upper limb volume, symptoms, and function</td> <td> </td> <td> <p>Upper limb volume increased in both groups over first two years but was less likely to stay increased in SLNB group after the first month.</p> <p>Reduction in upper limb movement was greater in ALND group up to six months but similar between groups from one to three years.</p> Subjective ratings of upper limb swelling, symptoms, dysfunction, and disability over three years were worse in ALND group.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Sentinella/GIVOM (2008)<sup>[8]</sup></td> <td>697 women with &lt;3 cm breast cancer</td> <td>56 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td>DFS: no difference</td> <td>OS: no difference</td> <td>SLNB group had less lymphedema, restriction of shoulder mobility, and numbness.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Canavese (2009)<sup>[9]</sup></td> <td>225 patients with &lt;3 cm primary invasive cancer clinically node-negative</td> <td>66 months</td> <td>ALND</td> <td>SLNB alone (if negative)</td> <td> <p>OS: no difference</p> Axillary recurrence: none in SLNB group</td> <td>DFS: no difference</td> <td>NR</td> </tr> <tr> <td class="subtitle2_left" colspan="8">RCTs comparing ALND with no further axillary treatment for patients with positive sentinel nodes</td> </tr> <tr class="divider_bottom"> <td class="indent1">Z0011 (2011)<sup>[10]</sup></td> <td> <p>856 women with T1-2 breast cancer, and 1-2 metastatic nodes by SLNB</p> All underwent lumpectomy and whole-breast irradiation</td> <td> <p>76 months<sup>[10]</sup></p> 111 months<sup>[11]</sup> </td> <td>ALND</td> <td>No further axillary treatment</td> <td>OS: no difference<sup>[10]</sup></td> <td> <p>DFS: no difference<sup>[10,11]</sup></p> <p>Nodal recurrence: no difference<sup>[11]</sup></p> Local regional recurrence: no difference<sup>[11]</sup></td> <td> <p>Wound infections, axillary seromas, and paresthesias were more common in ALND group.<sup>[10]</sup></p> Lymphedema was more common by self-reporting and by arm circumference measurement in ALND group.<sup>[10]</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">IBCSG 23-01 (2013)<sup>[12]</sup></td> <td>931 women with &lt;5 cm breast cancer and 1 or more micrometastatic sentinel nodes</td> <td>60 months</td> <td>ALND</td> <td>No further axillary treatment</td> <td>DFS: no difference</td> <td> <p>OS: no difference</p> Breast cancer events: no difference</td> <td>ALND caused more lymphedema, sensory neuropathy, and motor neuropathy than the no further treatment group.</td> </tr> <tr> <td class="subtitle2_left" colspan="8">RCT comparing ALND with axillary radiotherapy for patients with positive sentinel nodes</td> </tr> <tr> <td class="indent1">AMAROS (2014)<sup>[13]</sup></td> <td> <p>4805 patients randomized, 1425 patients had positive sentinel node(s)</p> 744 assigned to ALND, 681 to axillary radiotherapy</td> <td>73 months</td> <td>ALND</td> <td>Axillary radiation</td> <td>Axillary recurrence: 0.43 percent ALND versus 1.19 percent axillary radiation</td> <td> <p>OS: no difference</p> DFS: no difference</td> <td>ALND caused more lymphedema at one, three, and five years.</td> </tr> </tbody></table></div><div class="graphic_footnotes">RCT: randomized controlled trial; SLNB: sentinel lymph node biopsy; ALND: axillary lymph node dissection; OS: overall survival; DFS: disease-free survival; NR: not reported.</div><div class="graphic_reference">References:

<ol>
<li>Krag DN, Anderson SJ, JulianTB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11:927.</li>
<li>Ashikaga, T, Krag, DN, Land, SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010; 102:111.</li>
<li>Mansel, RE, Fallowfield, L, Kissin, M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599.</li>
<li>Veronesi, U, Viale, G, Paganelli, G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010; 251:595.</li>
<li>Veronesi, U, Paganelli, G, Viale, G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006; 7:983.</li>
<li>Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23:4312.</li>
<li>Wetzig N, Gill PG, Zannino D, et al. Sentinel lymph node based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial. Ann Surg Oncol 2015; 22:17.</li>
<li>Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247:207.</li>
<li>Canavese G, Catturich A, Vecchio C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 2009; 20:1001.</li>
<li>Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569.</li>
<li>Giuliano AE, Ballman K, McCall L, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg 2016; 264:413.</li>
<li>Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14:297.</li>
<li>Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15:1303.</li>
</ol></div><div id="graphicVersion">Graphic 109651 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
